Can AI predict individual cancer relapse risk using tumor genetic sequencing ?
Cast your vote — then read what our editor and the AI models found.
Cancer relapse depends on a complex interplay of genetic mutations, tumor microenvironment, and treatment response. Personalized medicine aims to predict relapse risk by analyzing tumor genomics, but integrating vast datasets remains challenging for human clinicians. AI could accelerate this process by identifying patterns linked to recurrence in high-dimensional data.
AI systems can now leverage tumor whole-exome or RNA sequencing alongside clinical variables to produce individualized recurrence-risk scores that outperform traditional pathology alone. For example, commercial platforms such as Oncotype DX AR-V7 and FoundationOne Hemo use gene-expression panels to estimate relapse probability in breast, prostate and hematologic cancers, and deep-learning models trained on TCGA data achieve AUCs around 0.75–0.85 for several tumor types. Regulatory-cleared tools remain largely prognostic rather than predictive of therapy response, and real-world validation outside curated cohorts is still limited.
— Enriched May 12, 2026 · Source: Nature Medicine
Suggest a tag
A missing concept on this topic? Suggest it and admin reviews.
Status last checked on May 12, 2026.
Gallery
What the audience thinks
No 33% · Yes 33% · Maybe 33% 3 votesDiscussion
no comments⚖ 1 jury check · most recent 1 day ago
Each row is a separate jury check. Jurors are AI models (identities kept neutral on purpose). Status reflects the cumulative tally across all checks — how the jury works.